420,569 Shares in ADMA Biologics, Inc. (NASDAQ:ADMA) Bought by Royce & Associates LP

Royce & Associates LP purchased a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) in the fourth quarter, Holdings Channel reports. The firm purchased 420,569 shares of the biotechnology company’s stock, valued at approximately $7,213,000.

Several other institutional investors have also added to or reduced their stakes in the company. Natixis Advisors LLC purchased a new stake in ADMA Biologics in the 3rd quarter worth approximately $345,000. Mutual of America Capital Management LLC bought a new position in shares of ADMA Biologics during the third quarter valued at approximately $701,000. Thrivent Financial for Lutherans purchased a new stake in ADMA Biologics in the third quarter worth $3,802,000. First Turn Management LLC bought a new stake in ADMA Biologics in the third quarter valued at $13,293,000. Finally, Aviance Capital Partners LLC purchased a new position in ADMA Biologics during the 3rd quarter valued at $229,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Price Performance

Shares of NASDAQ:ADMA opened at $18.71 on Wednesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The firm has a market cap of $4.42 billion, a price-to-earnings ratio of 66.82 and a beta of 0.60. The business has a 50-day simple moving average of $16.67 and a two-hundred day simple moving average of $17.98. ADMA Biologics, Inc. has a fifty-two week low of $5.88 and a fifty-two week high of $23.64.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.